Anandamide

Anandamide is a lipid of Fatty Acyls (FA) class. Anandamide is associated with abnormalities such as Dehydration. The involved functions are known as Process, Phenomenon, Phosphorylation, Catabolic Process and Gene Expression. Anandamide often locates in Nuchal region, Microglial and Hepatic. The associated genes with Anandamide are SGPL1 gene, SPTLC1 gene, RPSA gene, KDSR gene and SMPD1 gene. The related lipids are Sphingolipids, Lipopolysaccharides, Lysophospholipids, LYSO-PC and lysophosphatidylethanolamine.

Cross Reference

Introduction

To understand associated biological information of Anandamide, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Anandamide?

Anandamide is suspected in Dehydration and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Anandamide

MeSH term MeSH ID Detail
Sleep Disorders, Intrinsic D020919 1 associated lipids
Headache Disorders, Secondary D051271 1 associated lipids
Somatosensory Disorders D020886 1 associated lipids
Orthostatic Intolerance D054971 1 associated lipids
Ocular Hypotension D015814 2 associated lipids
Vascular System Injuries D057772 2 associated lipids
Amnesia, Anterograde D020324 2 associated lipids
Substance-Related Disorders D019966 2 associated lipids
Schistosomiasis japonica D012554 3 associated lipids
Bulimia D002032 3 associated lipids
Acute Pain D059787 3 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Impotence, Vasculogenic D018783 4 associated lipids
Urinary Incontinence D014549 4 associated lipids
Picornaviridae Infections D010850 4 associated lipids
Fibromyalgia D005356 4 associated lipids
Urinary Bladder Diseases D001745 4 associated lipids
Pregnancy, Ectopic D011271 5 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Brain Concussion D001924 5 associated lipids
Muscle Spasticity D009128 5 associated lipids
Sleep Deprivation D012892 5 associated lipids
Brain Damage, Chronic D001925 6 associated lipids
Cholangiocarcinoma D018281 7 associated lipids
Anorexia D000855 8 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Morphine Dependence D009021 9 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Shock, Septic D012772 11 associated lipids
Overweight D050177 11 associated lipids
Hyperkinesis D006948 11 associated lipids
Hepatitis D006505 11 associated lipids
Migraine Disorders D008881 11 associated lipids
Learning Disorders D007859 11 associated lipids
Hypertension, Portal D006975 12 associated lipids
Neoplasms D009369 13 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Multiple Sclerosis D009103 13 associated lipids
Bradycardia D001919 13 associated lipids
Cardiomyopathy, Dilated D002311 15 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Celiac Disease D002446 16 associated lipids
Ventricular Fibrillation D014693 16 associated lipids
Parkinson Disease, Secondary D010302 17 associated lipids
Mycoses D009181 18 associated lipids
Pancreatitis, Acute Necrotizing D019283 18 associated lipids
Bronchial Spasm D001986 18 associated lipids
Cough D003371 19 associated lipids
Hypothermia D007035 19 associated lipids
Peptic Ulcer D010437 19 associated lipids
Ataxia D001259 20 associated lipids
Brain Edema D001929 20 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Breast Neoplasms D001943 24 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Hyperemia D006940 25 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Hyperinsulinism D006946 27 associated lipids
Endotoxemia D019446 27 associated lipids
Neuralgia D009437 28 associated lipids
Obesity D009765 29 associated lipids
Catalepsy D002375 30 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Memory Disorders D008569 33 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Epilepsy D004827 35 associated lipids
Fever D005334 35 associated lipids
Nervous System Diseases D009422 37 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Hypotension D007022 41 associated lipids
Hyperalgesia D006930 42 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Fatty Liver D005234 48 associated lipids
Nerve Degeneration D009410 53 associated lipids
Pain D010146 64 associated lipids
Reperfusion Injury D015427 65 associated lipids
Neuroblastoma D009447 66 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Melanoma D008545 69 associated lipids
Colitis D003092 69 associated lipids
Stomach Ulcer D013276 75 associated lipids
Alzheimer Disease D000544 76 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Seizures D012640 87 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Insulin Resistance D007333 99 associated lipids
Weight Gain D015430 101 associated lipids
Glioma D005910 112 associated lipids
Hypertension D006973 115 associated lipids
Per page 10 20 50 100 | Total 105

PubChem Associated disorders and diseases

What pathways are associated with Anandamide

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Anandamide?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Anandamide?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Anandamide?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Anandamide?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Anandamide?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Anandamide

Download all related citations
Per page 10 20 50 100 | Total 2222
Authors Title Published Journal PubMed Link
Witting A et al. Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. 2004 J. Neurochem. pmid:15189359
Hill MN et al. Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity. 2007 J. Neurochem. pmid:17561935
Subbanna S et al. Postnatal ethanol exposure alters levels of 2-arachidonylglycerol-metabolizing enzymes and pharmacological inhibition of monoacylglycerol lipase does not cause neurodegeneration in neonatal mice. 2015 J. Neurochem. pmid:25857698
Sarker KP et al. ASK1-p38 MAPK/JNK signaling cascade mediates anandamide-induced PC12 cell death. 2003 J. Neurochem. pmid:12641726
Wu X et al. Alteration of endocannabinoid system in human gliomas. 2012 J. Neurochem. pmid:22176552
Hansen HS et al. Characterization of glutamate-induced formation of N-acylphosphatidylethanolamine and N-acylethanolamine in cultured neocortical neurons. 1997 J. Neurochem. pmid:9231736
Butt C et al. Endogenous cannabinoid anandamide inhibits nicotinic acetylcholine receptor function in mouse thalamic synaptosomes. 2008 J. Neurochem. pmid:18194436
Basavarajappa BS and Hungund BL Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidylethanolamine in SK-N-SH cells. 1999 J. Neurochem. pmid:9930723
De Lago E et al. Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. 2006 J. Neurochem. pmid:16899063
Hansen HH et al. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. 2001 J. Neurochem. pmid:11579150
Di Marzo V et al. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats. 2000 J. Neurochem. pmid:10737621
Maccarrone M et al. Anandamide degradation and N-acylethanolamines level in wild-type and CB1 cannabinoid receptor knockout mice of different ages. 2001 J. Neurochem. pmid:11461969
Mestre L et al. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. 2005 J. Neurochem. pmid:15748152
Oz M et al. The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism. 2010 J. Neurochem. pmid:20050977
Wiles AL et al. N-Arachidonyl-glycine inhibits the glycine transporter, GLYT2a. 2006 J. Neurochem. pmid:16899062
Navarrete CM et al. Opposite effects of anandamide and N-arachidonoyl dopamine in the regulation of prostaglandin E and 8-iso-PGF formation in primary glial cells. 2009 J. Neurochem. pmid:19200337
Cadogan AK et al. Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. 1997 J. Neurochem. pmid:9282935
Hansen HH et al. Determination of the phospholipid precursor of anandamide and other N-acylethanolamine phospholipids before and after sodium azide-induced toxicity in cultured neocortical neurons. 2000 J. Neurochem. pmid:10899965
Berger C et al. Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? 2004 J. Neurochem. pmid:15009671
Hillard CJ et al. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. 1997 J. Neurochem. pmid:9231721
De Petrocellis L et al. The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. 2001 J. Neurochem. pmid:11413249
Bisogno T Endogenous cannabinoids: structure and metabolism. 2008 J. Neuroendocrinol. pmid:18426492
Capasso R and Izzo AA Gastrointestinal regulation of food intake: general aspects and focus on anandamide and oleoylethanolamide. 2008 J. Neuroendocrinol. pmid:18426498
Stefano GB Autoimmunovascular regulation: morphine and anandamide and ancondamide stimulated nitric oxide release. 1998 J. Neuroimmunol. pmid:9610675
Eisenstein TK et al. Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. 2007 J. Neuroimmunol. pmid:17640739
Schwarz H et al. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. 1994 J. Neuroimmunol. pmid:7962480
De Laurentiis A et al. The hypothalamic endocannabinoid system participates in the secretion of oxytocin and tumor necrosis factor-alpha induced by lipopolysaccharide. 2010 J. Neuroimmunol. pmid:20207018
Hollis JH et al. The endocannabinoid arachidonylethanolamide attenuates aspects of lipopolysaccharide-induced changes in energy intake, energy expenditure and hypothalamic Fos expression. 2011 J. Neuroimmunol. pmid:21262543
Malfitano AM et al. Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis. 2006 J. Neuroimmunol. pmid:16239036
Di Filippo M et al. Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. 2008 J. Neurol. Neurosurg. Psychiatr. pmid:18535023
Jean-Gilles L et al. Plasma endocannabinoid levels in multiple sclerosis. 2009 J. Neurol. Sci. pmid:19695579
Contassot E et al. Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. 2004 J. Neuropathol. Exp. Neurol. pmid:15453094
Ali AB Presynaptic Inhibition of GABAA receptor-mediated unitary IPSPs by cannabinoid receptors at synapses between CCK-positive interneurons in rat hippocampus. 2007 J. Neurophysiol. pmid:17567776
Fischbach T et al. Effects of anandamide and noxious heat on intracellular calcium concentration in nociceptive drg neurons of rats. 2007 J. Neurophysiol. pmid:17581853
Uhelski ML et al. Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy. 2015 J. Neurophysiol. pmid:25505113
Fan P Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. 1995 J. Neurophysiol. pmid:7760148
Fisyunov A et al. Cannabinoids modulate the P-type high-voltage-activated calcium currents in purkinje neurons. 2006 J. Neurophysiol. pmid:16738209
De-May CL and Ali AB Cell type-specific regulation of inhibition via cannabinoid type 1 receptors in rat neocortex. 2013 J. Neurophysiol. pmid:23054605
Morisset V and Urban L Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. 2001 J. Neurophysiol. pmid:11431486
Twitchell W et al. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. 1997 J. Neurophysiol. pmid:9242259
Ahern GP et al. Extracellular cations sensitize and gate capsaicin receptor TRPV1 modulating pain signaling. 2005 J. Neurosci. pmid:15917451
Tabatadze N et al. Sex Differences in Molecular Signaling at Inhibitory Synapses in the Hippocampus. 2015 J. Neurosci. pmid:26269634
Gómez R et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. 2002 J. Neurosci. pmid:12417686
Gray JM et al. Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. 2015 J. Neurosci. pmid:25740517
Wang ZJ et al. Cannabinoid receptor-mediated regulation of neuronal activity and signaling in glomeruli of the main olfactory bulb. 2012 J. Neurosci. pmid:22723687
Xiong W et al. A common molecular basis for exogenous and endogenous cannabinoid potentiation of glycine receptors. 2012 J. Neurosci. pmid:22496565
Franklin A et al. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. 2003 J. Neurosci. pmid:12944505
Shen Y et al. A transient receptor potential-like channel mediates synaptic transmission in rod bipolar cells. 2009 J. Neurosci. pmid:19439586
Derkinderen P et al. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. 2003 J. Neurosci. pmid:12657697
Clement AB et al. Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. 2003 J. Neurosci. pmid:12736361
Marinelli S et al. Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. 2003 J. Neurosci. pmid:12716921
Massa F et al. Alterations in the hippocampal endocannabinoid system in diet-induced obese mice. 2010 J. Neurosci. pmid:20445053
Tognetto M et al. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. 2001 J. Neurosci. pmid:11160380
Cadas H et al. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. 1996 J. Neurosci. pmid:8656287
van der Stelt M et al. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. 2001 J. Neurosci. pmid:11698588
Beltramo M et al. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. 2000 J. Neurosci. pmid:10777802
Lerner TN et al. Endocannabinoid signaling mediates psychomotor activation by adenosine A2A antagonists. 2010 J. Neurosci. pmid:20147543
Garami A et al. Thermoregulatory phenotype of the Trpv1 knockout mouse: thermoeffector dysbalance with hyperkinesis. 2011 J. Neurosci. pmid:21289181
Justinova Z et al. The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. 2005 J. Neurosci. pmid:15944392
Subbanna S et al. Anandamide-CB1 receptor signaling contributes to postnatal ethanol-induced neonatal neurodegeneration, adult synaptic, and memory deficits. 2013 J. Neurosci. pmid:23575834
Dinis P et al. Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. 2004 J. Neurosci. pmid:15601931
Akerman S et al. Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and "triptan" receptors: implications in migraine. 2013 J. Neurosci. pmid:24027286
Ade KK and Lovinger DM Anandamide regulates postnatal development of long-term synaptic plasticity in the rat dorsolateral striatum. 2007 J. Neurosci. pmid:17329438
Khlaifia A et al. Anandamide, cannabinoid type 1 receptor, and NMDA receptor activation mediate non-Hebbian presynaptically expressed long-term depression at the first central synapse for visceral afferent fibers. 2013 J. Neurosci. pmid:23904599
Kim D and Thayer SA Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. 2001 J. Neurosci. pmid:11319244
Khasabova IA et al. A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. 2008 J. Neurosci. pmid:18971457
Veldhuis WB et al. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases. 2003 J. Neurosci. pmid:12764100
Cadas H et al. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. 1997 J. Neurosci. pmid:9006968
Khasabova IA et al. Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. 2012 J. Neurosci. pmid:22593077
Qin N et al. TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. 2008 J. Neurosci. pmid:18550765
Chemin J et al. Neuronal T-type alpha 1H calcium channels induce neuritogenesis and expression of high-voltage-activated calcium channels in the NG108-15 cell line. 2002 J. Neurosci. pmid:12177183
Gubellini P et al. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. 2002 J. Neurosci. pmid:12177188
Kim SR et al. Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro. 2005 J. Neurosci. pmid:15659603
Thomas EA et al. Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system. 1997 J. Neurosci. Res. pmid:9452020
Bari M et al. Cholesterol-dependent modulation of type 1 cannabinoid receptors in nerve cells. 2005 J. Neurosci. Res. pmid:15920744
Molina-Holgado F et al. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. 2002 J. Neurosci. Res. pmid:11891798
Arias-Carrión O et al. Biochemical modulation of the sleep-wake cycle: endogenous sleep-inducing factors. 2011 J. Neurosci. Res. pmid:21557294
Bajo M et al. Differential alteration of hippocampal excitatory synaptic transmission by cannabinoid ligands. 2009 J. Neurosci. Res. pmid:18816788
Shinjyo N et al. Impact of omega-6 polyunsaturated fatty acid supplementation and γ-aminobutyric acid on astrogliogenesis through the endocannabinoid system. 2013 J. Neurosci. Res. pmid:23633391
Bannerman P et al. Early migratory rat neural crest cells express functional gap junctions: evidence that neural crest cell survival requires gap junction function. 2000 J. Neurosci. Res. pmid:10972957
Mennella I et al. Food Liking Enhances the Plasma Response of 2-Arachidonoylglycerol and of Pancreatic Polypeptide upon Modified Sham Feeding in Humans. 2015 J. Nutr. pmid:26180248
Batetta B et al. Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. 2009 J. Nutr. pmid:19549757
Hutchins-Wiese HL et al. Hind limb suspension and long-chain omega-3 PUFA increase mRNA endocannabinoid system levels in skeletal muscle. 2012 J. Nutr. Biochem. pmid:22051448
Battista N et al. Abnormal anandamide metabolism in celiac disease. 2012 J. Nutr. Biochem. pmid:22209002
Hutchins HL et al. Eicosapentaenoic acid decreases expression of anandamide synthesis enzyme and cannabinoid receptor 2 in osteoblast-like cells. 2011 J. Nutr. Biochem. pmid:20951563
Gómez R et al. Endogenous cannabinoid anandamide impairs cell growth and induces apoptosis in chondrocytes. 2014 J. Orthop. Res. pmid:24902823
Di Marzo M et al. Synthesis, conformational analysis and CB1 binding affinity of hairpin-like anandamide pseudopeptide mimetics. 2006 J. Pept. Sci. pmid:16534762
Chiba T et al. A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells. 2011 J. Pharm. Pharmacol. pmid:21492165
Hayase T et al. Protective effects of cannabinoid receptor agonists against cocaine and other convulsant-induced toxic behavioural symptoms. 2001 J. Pharm. Pharmacol. pmid:11732755
Porter AC et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. 2002 J. Pharmacol. Exp. Ther. pmid:12023533
Patel S et al. Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. 2003 J. Pharmacol. Exp. Ther. pmid:12808005
Snider NT et al. The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. 2008 J. Pharmacol. Exp. Ther. pmid:18698000
McDougle DR et al. Endocannabinoids anandamide and 2-arachidonoylglycerol are substrates for human CYP2J2 epoxygenase. 2014 J. Pharmacol. Exp. Ther. pmid:25277139
Ishioka N and Bukoski RD A role for N-arachidonylethanolamine (anandamide) as the mediator of sensory nerve-dependent Ca2+-induced relaxation. 1999 J. Pharmacol. Exp. Ther. pmid:10087011
Matias I et al. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. 2004 J. Pharmacol. Exp. Ther. pmid:14757851
Smith PB et al. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. 1994 J. Pharmacol. Exp. Ther. pmid:8035318
Akerman S et al. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. 2004 J. Pharmacol. Exp. Ther. pmid:14718591
Trezza V and Vanderschuren LJ Divergent effects of anandamide transporter inhibitors with different target selectivity on social play behavior in adolescent rats. 2009 J. Pharmacol. Exp. Ther. pmid:18948500
McVey DC et al. Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). 2003 J. Pharmacol. Exp. Ther. pmid:12538826
Showalter VM et al. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. 1996 J. Pharmacol. Exp. Ther. pmid:8819477